Answers are grounded in this paper and cite their sources.
Background Selective orexin‐2 receptor (OX2R) agonists show efficacy. Between‐trial variability and safety uncertainty warrant pooled assessment. Objective We evaluated treatment effects in narcolepsy Type 1. We assessed pooled benefits, harms, and efficacy robustness. Methods Five databases and two trial registries were searched. Searches extended through September 15, 2026. Eligible trials evaluated repeated‐dose oral selective OX2R agonists. Trials were randomized, parallel, double‐blind, and placebo‐controlled. Shared‐placebo comparisons were combined using generalized least squares. Random‐effects models pooled efficacy and overall adverse events. Between‐study variance used restricted maximum‐likelihood estimation. Confidence intervals used the modified Knapp–Hartung method. Sparse safety outcomes used Mantel–Haenszel common‐effect risk ratios. Risk of bias was assessed using RoB 2. Results Five trials randomized 550 participants over 6–12 weeks. Efficacy estimates compared active treatment with placebo. Maintenance of Wakefulness Test improvement averaged 21.91 min (95% CI: 15.11–28.70; I 2 = 84.5%). Epworth Sleepiness Scale scores decreased by 9.28 points (95% CI: 7.96–10.60; I 2 = 0%). Weekly cataplexy rates were lower with treatment (incidence rate ratio, 0.34; 95% CI: 0.22–0.55; I 2 = 36.1%). Treatment‐emergent adverse events increased (risk ratio, 1.89; 95% CI: 1.44–2.48). Insomnia, urinary symptoms, and salivary hypersecretion increased. Adverse‐event discontinuation estimates remained imprecise (risk ratio, 3.73; 95% CI: 0.50–28.03). Excluding TAK‐994 yielded similar efficacy estimates. Residual wakefulness heterogeneity remained substantial ( I 2 = 69.9%). Conclusion Studied regimens improved wakefulness, sleepiness, and cataplexy. Benefits persisted after excluding TAK‐994. However, wakefulness effects varied substantially across trials. Treatment increased several clinically relevant adverse events. Long‐term safety and uncommon harms remain uncertain.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: